Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Clofarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 8/20 | 0.69 |
| ▸ | CD99 | P14209 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofarabine SCHEMBL12595105 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL17752021 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL1467619 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL4570563 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL5975001 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL12139443 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL23620882 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL15468200 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL10026375 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL18739936 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 33796 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| WO-2026101232-A1 | POLYMER COMPOUND FOR CELL SURFACE MODIFICATION FOR IMPROVING DRUG DELIVERY EFFICIENCY | 동국대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| CN-122028920-A | Method for treating hematological cancer | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | claimed |
| EP-1261350-A1 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-$g(b)-D-ARABINOFURANOSYL)- i 9H /i -PURIN-6-AMINE | Southern Research Institute (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001010454-A9 | PHARMACEUTICAL COMPOSITION COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTION | AVENTIS PHARM PROD INC (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1143990-A3 | PHARMACEUTICAL COMPOSTIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Inc. (US) | 2002-03-27 | — | — | EP | claimed |
| EP-1143990-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001060383-A1 | METHODS FOR SYNTHESIZING 2-CHLORO-9-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE | SOUTHERN RESEARCH INSTITUTE (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001010454-A2 | PHARMACEUTICAL COMPOSITION COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTION | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2001-02-15 | — | — | WO | claimed |
| EP-1053012-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-22 | — | — | EP | claimed |
| WO-1999039732-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PEG-ASPARAGINASE FOR THE TREATMENT OF HIV INFECTIONS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-08-12 | — | — | WO | claimed |
| US-5661136-A | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | SOUTHERN RESEARCH INSTITUTE (US) | 1997-08-26 | — | — | US | claimed |
| EP-0314011-A2 | Purine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-05-03 | — | — | EP | claimed |